Reetika Bhardwaj
Principal @ Dolby Family Ventures
San Francisco, United States
Reetika Bhardwaj is a Series A investor at Dolby Family Ventures in San Francisco focused on Pharmaceutical and Biotechnology. Reetika Bhardwaj is based out of San Francisco, California, and is the Principal of Dolby Family Ventures and Board of Directors of MindImmune Therapeutics. Reetika Bhardwaj attended the University of Chicago Booth School of Business.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Reetika Bhardwaj invests in
Stages Reetika Bhardwaj invests in
Countries Reetika Bhardwaj invests in
Investment Focus
Industry
- Pharmaceutical 3 (100%)
- Biotechnology 2 (67%)
- Health Care 1 (33%)
- Neuroscience 1 (33%)
- Therapeutics 1 (33%)
Stage
- Series A 2 (67%)
- Series B 1 (33%)
Country
- United States 2 (67%)
- Germany 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Exciva
|
exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M / Series B / Jan 20, 2026 | |
MindImmune Therapeutics
|
MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated.Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs. | $15.2M / Series A / Nov 24, 2025 | |
Pretzel Therapeutics
|
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinatingfeatures that make it unlike any other organelle in the body. | $72.5M / Series A / Sep 12, 2022 |
Co-Investors
Andera Partners
2 deals together
Gimv
2 deals together
Google Ventures
2 deals together
Mubadala Capital Ventures
2 deals together
Angelini Ventures
1 deal together
Cambridge Innovation Capital
1 deal together
About Dolby Family Ventures
Dolby Family Ventures is an early stage venture firm focused on building great technology companies. They partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company’s development. Unlike many seed investors, They intend to continue to invest across future rounds in our successful portfoliocompanies.
Dolby Family Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Krowne
Managing Director
|
|||
David Dolby
CEO
|
|||
|
Kavan Canekeratne
Associate; Associate
|
|||
Pascal Levensohn
Senior Managing Director
|
|||
|
Reetika Bhardwaj
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Reetika Bhardwaj invest in?
Reetika Bhardwaj invests primarily in Pharmaceutical, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Reetika Bhardwaj last invest?
The most recent investment recorded for Reetika Bhardwaj closed in Jan 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
